Satipharm AG is the medical and health division of Harvest One. We specialize in
providing effective and innovative cannabis products to markets around the world with a primary focus on CBD treatments. Our CBD GelPells were one of the first prescription cannabis products used by patients in Australia and are widely available across the EU.
Currently, two separate Phase 2 trials are in development. One on pediatric refractory epilepsy is underway and another on multiple sclerosis is about to commence. Initial results have been predominantly positive.